Statins are said to protect against a wide range of diseases. We studied to what extent potential bias influences the results of studies on beneficial side effects of statins. We selected 8,188 atrial fibrillation patients who started treatment with anticoagulants at the Leiden Anticoagulation Clinic in the Netherlands between 2003 and 2009 and experienced 1,683 minor and 451 major bleeds during 18,105 person-years of follow-up. Statins were associated with a risk reduction of 9% for bleeds (hazard ratio = 0.91, 95% confidence interval: 0.82, 1.00). Additionally, analyses were stratified by age, incident users ( patients who started statins during follow-up, i.e., an inception cohort), and prevalent statin users (statin users at baseline), as restriction to incident users avoids overoptimistic risk estimates. After stratification, the protective associations disappeared or reversed (range of hazard ratios = 0.99-3.22), except for patients aged 75 years or older. This remaining association could be due to another bias as, according to guidelines, in the elderly, statins should be prescribed only to those with a reasonable life expectancy. This could have resulted in a comparison of fit statin users with less fit nonstatin users (healthy user effect). The apparent protective association of statins on bleeds may be due to bias. We recommend stratification by age and incident and prevalent statin use when studying associations of statins with disease outcomes to avoid overoptimistic risk estimates. bias (epidemiology); cohort studies; coumarins; hemorrhage; hydroxymethylglutaryl-CoA reductase inhibitors Abbreviations: CI, confidence interval; INR, international normalized ratio.
Statins reduce atherosclerosis (1) and, consequently, arterial cardiovascular disease (2), but they are also known for their wide range of unintended beneficial effects. Examples in which statin use is associated with lower risk for disease include, among others, Alzheimer disease (3), Parkinson disease (4), depression (5), chronic obstructive pulmonary disease (6) , venous thrombosis (7, 8) , pneumonia (9) , and fractures (10) . It has been argued that, if many cures are attributed to a single drug, the drug may in fact be ineffective, and noncausal explanations such as bias should be sought (11) .
A possible bias that may lead to lower risk estimates in observational studies is so-called "prevalent user bias." This type of bias was described by Danaei et al. (12) when studying associations of statins with mortality. In a meta-analysis, they showed that the pooled, multivariate-adjusted mortality hazard ratio for statin use was 0.54 (95% confidence interval (CI): 0.45, 0.66) when comparing prevalent statin users (statin users at baseline) with nonusers. However, in order to get the most valid results, observational studies should attempt to mimic clinical trials. When selecting the observational studies that, like the randomized trial, compared patients who started using statins during follow-up (an inception cohort design or incident statin users) with nonusers, researchers have found that risk estimates of studies with incident statin users (hazard ratio = 0.77, 95% CI: 0.65, 0.91) were similar to those found in randomized controlled trials (hazard ratio = 0.84, 95% CI: 0.77, 0.91) (12, 13) .
Another type of bias may occur as the result of the prescription guidelines of statins: The Dutch guideline of 1999 states that statins should be prescribed only to individuals with a life expectancy of at least 5 years (14) . The renewed guideline from 2006 states that statins should be prescribed to individuals with a reasonable life expectancy who are not severely ill (15) . A comparison of those who start using statins during follow-up (incident statin user) with nonusers among the elderly may therefore result in a comparison of elderly persons with a reasonable life expectancy with those with a short life expectancy, resulting in a so-called "healthy user effect."
The present study was performed to examine to what extent these potential biases influence its results and conclusions. For this purpose, we performed a cohort study on the association of statin use and bleeding risk during treatment with vitamin K antagonists.
METHODS

Study population
A cohort was selected consisting of all patients who were 50 years or older and treated for atrial fibrillation at the Leiden Anticoagulation Clinic starting between January 2003 and December 2009 (8,188 patients). As patients could interrupt their treatment with vitamin K antagonist and start again, these patients had 8,853 treatment periods altogether.
Data collection
Patients' characteristics and outcomes were collected from the computerized patient records from the Leiden Anticoagulation Clinic (16) . At the anticoagulation clinic, a blood sample is collected every 1-6 weeks to measure the international normalized ratio (INR). A standard short history is obtained with every venipuncture regarding comedications, intercurrent illness, planned surgery, and bleeding complications (16) . Baseline data of the cohort include age at start of vitamin K antagonist therapy, sex, main indication for vitamin K antagonist therapy, type of vitamin K antagonist (acenocoumarol or phenprocoumon), INR target range (2.5-3.5 or 3.0-4.0), and concomitant medication use. The starting date of medication use (for this study: statins, antiplatelet drugs, antidiabetic agents, and antihypertensive medications) was reported by the patient or the drug-dispensing pharmacy. Diabetes mellitus and hypertension were defined from the first date of use of any antidiabetic agent (oral and/or parenteral) or antihypertensive drug, respectively. Patients were considered exposed to statins and antiplatelet drugs from the first date of use of the drugs until the end date of the study period. Neither informed consent nor approval by a medical ethics committee is, according to Dutch law, required for studies in which data are collected from the records by a member of the treatment team.
Outcomes
Nontraumatic major bleeding events were classified by physicians of the Leiden Anticoagulation Clinic. Bleeding events that required hospitalization or blood transfusion, that were symptomatic in a critical area or organ, or led to death were classified as major (17) . Nontraumatic minor bleeding events included all hemorrhages that were not classified as major and were categorized as such by the Anticoagulant Clinic's physicians and/or nurses. We excluded traumatic bleeding events because statins could protect against nontraumatic bleeds, while their pharmacological actions are not likely to protect against bleeding events caused by trauma.
Statistical analyses
For every treatment with vitamin K antagonists, persontime was calculated from the start of treatment with vitamin K antagonists until the bleeding event, death, moving to a city that was not covered by the Leiden Anticoagulation Clinic, end of treatment, or end of the study period (December 31, 2009), whichever occurred first. When calculating the persontime for major bleeds, we ignored the occurrence of minor bleeds and vice versa. We used a Cox regression model, with time-dependent covariates to estimate hazard ratios and 95% confidence intervals. The proportionality of the hazards assumption was tested by analysis of Schoenfeld residuals, and for this analysis statistical significance was set at the 5% level.
Patients were classified in 3 age groups (50-64 years, 65-74 years, and 75 years or older) to study age-specific associations. Age-specific associations were expected as a potential healthy user effect in elderly patients may be present as a result of the prescription guidelines (14, 15) .
We adjusted for the confounding factors sex, INR target range (3.0-4.0 vs. 2.5-3.5), diabetes mellitus (time dependently), hypertension (time dependently), and use of antiplatelet drugs (time dependently) in the simple adjusted model. The fully adjusted model also included age (by the abovementioned age categories for the overall risk estimates and continuously for analyses within age groups, because confounding due to age can still be present within an age group). We performed 3 different analyses. First, we compared all statin users (as a time-dependent variable) with nonstatin users. Then, incident users were compared with nonusers by using only the patients who did not use statins at baseline. In the last analysis, prevalent users were compared with nonusers; if a patient started to use statins after baseline, his follow-up was censored.
All analyses were performed with the R, version 2.15.2, language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Of 8,188 patients, 7,592 had 1, 536 had 2, 53 had 3, 5 patients had 4, and 2 patients had 5 treatment periods during the study period. Patients with multiple treatment periods were treated for a period with vitamin K antagonists, which was discontinued for some time and then restarted. A common reason to discontinue vitamin K antagonist treatment was a successful cardioversion (either chemical or mechanical) (18) .
The mean age at baseline was 74 (range, 50-103) years, and 4,847 patients (55%) were men. The INR target range was 2.5-3.5 in 8,659 (98%) treatment periods as recommended for atrial fibrillation in the Netherlands (19) , and phenprocoumon was used during 8,009 (91%) treatment periods. Statin users were more frequently male than were nonstatin users. The prevalence of hypertension, diabetes, and use of antiplatelet drugs was higher in statin users than nonstatin users ( Table 1) . Stratification of incident statin users by age showed that patients aged 50-64 years were more frequently male and had a lower prevalence of diabetes mellitus than patients aged 75 years or older.
During a total follow-up of 15,008 person-years for all bleeds, 15,231 person-years for minor bleeding events, and 18,105 person-years for major bleeding events, 1,991 patients experienced any bleed, 1,683 experienced a minor bleed, and 451 patients experienced a major bleeding event. The incidence rate was 133 (95% CI: 127, 139) per 1,000 person-years for all, 110 (95% CI: 105, 116) per 1,000 person-years for minor, and 25 (95% CI: 23, 27) per 1,000 person-years for major bleeding complications. The incidence rates of all, major, and minor bleeding complications increased with age (Figure 1) , and the most common sites of major bleeds were the gastrointestinal tract and cranium (Web Table 1 available at http://aje.oxfordjournals.org/).
Statins were used during 3,330 treatment periods and initiated during 842 treatment periods (the latter were considered incident statin users). Overall, the crude hazard ratio of statin use (prevalent and incident statin use combined) versus nonstatin use was 0.90 (95% CI: 0.81, 0.99) for all bleeds, 0.91 (95% CI: 0.82, 1.01) for minor bleeds, and 0.90 (95% CI: 0.75, 1.11) for major bleeds (Table 2) . Adjustment for sex, INR target range, diabetes, hypertension, and use of antiplatelet drugs resulted in hazard ratios of 0.88 (95% CI: 0.80, 0.97) for all, 0.83 (95% CI: 0.67, 1.02) for major, and 0.90 (95% CI: 0.81, 1.01) for minor bleeds (Table 2 ). After further adjustment for age, these hazard ratios increased toward unity (Table 2) . After stratification by age, no protective risk estimates were found in patients aged 50-64 years and 65-74 years, but protective risk estimates were still found in the oldest patients for all outcomes (Table 3 ). Restriction to incident statin users ( Figure 2 ) and nonusers yielded higher risk estimates than did restriction to prevalent statin users and nonusers for all outcomes (incident users vs. nonusers for all bleeding complications: fully adjusted hazard ratio = 1.08, 95% CI: 0.90, 1.32; minor bleeding complications fully adjusted hazard ratio = 1.18, 95% CI: 0.96, 1.45; major bleeding complications fully adjusted hazard ratio = 0.93, 95% CI: 0.63, 1.36). Similar results were found in all age groups, except for major 
DISCUSSION
This study shows that statin use initially seemed to reduce the risk of minor and major bleeding events by 9% in the overall straightforward analysis (i.e., before we stratified the analysis by age and incident and prevalent statin users). However, after restriction to incident statin users, protective risk estimates largely disappeared or even reversed. After stratification by age, the risk estimates showed a protective association in patients of 75 years or older. Associations in ( pharmaco)epidemiologic studies can be due to causal mechanisms but also to confounding or bias (20) . As potential explanations for the associations found in this study, causal mechanisms, confounding, and bias were considered.
The association of statin use with bleeding events during treatment with vitamin K antagonists in the initial analysis of this study (fully adjusted hazard ratio = 0.91, 95% CI: 0.82, 1.00) was similar to the association that was previously found by Douketis et al. (21) (adjusted odds ratio = 0.91, 95% CI: 0.77, 1.07). Douketis et al. suspected that this protective association was due to bias. As shown in this study, bias could partially be due to a comparison of prevalent statin users with nonusers, which is in line with what was described in the meta-analysis by Danaei et al. (12) . This bias is not restricted only to statin therapy. Hernán et al. (22) showed that it is also present in studies on the effects of hormone replacement therapy on coronary heart disease when current ( prevalent) drug users instead of initiators (incident drug users) are compared with nonusers (23) . The results of these studies (12, 22) along with those of the present study suggest that comparisons of drug initiators with nonusers yield more reliable risk estimates than comparisons of prevalent drug users with nonusers when studying associations of drugs on disease outcomes. Another explanation for an association may be a causal effect, which is usually based on potential mechanisms from literature. Statins are known for their inhibitory effects on platelet function and their raising levels of procoagulant factors (24, 25) . These effects may explain the risk estimates indicative of an increased risk for bleeds of incident statin users as compared with nonusers in patients aged 50-64 years (hazard ratio = 1.18-3.22) and 65-74 years (hazard ratio = 1.11-1.31). However, this potential explanation of the found associations is not in line with the results in patients aged 75 years or older.
Another bias we will consider is healthy user bias due to prescription guidelines. The guidelines state that starting statins in elderly patients should be restricted to relatively healthy individuals (14, 15) . Especially in the elderly who started using a statin, these guidelines may result in a comparison of healthy elderly who started using a statin with less healthy ones who did not start using a statin, resulting in healthy user bias. The guidelines may explain why risk estimates of statin use for major bleeds remained protective in the oldest patients (aged 75 years or older) when considering only incident statin use (fully adjusted hazard ratio = 0.73).
The last source of spurious associations we will discuss is confounding (20) . In this study, we were not able to fully adjust for confounding by indication and life style-dependent confounding factors (because, e.g., body mass index and cholesterol levels were unknown). The increased risk estimates found in patients aged 50-64 years may be attributable to residual confounding, as these patients may have received statins as the result of an unhealthy life style. In addition, diabetes and hypertension were classified by first date of use of antidiabetic or antihypertensive drugs. Because diabetic or hypertensive treatment could have started a long time after patients developed these conditions, misclassification could have occurred. Therefore, adjustments for hypertension and diabetes may not have been perfect. Furthermore, comparing the results of our study with findings in randomized clinical trials (i.e., a "gold standard") in similar populations could give some indication of the amount of residual confounding, but unfortunately these trials have not been conducted.
In summary, a comparison of incident statin users with nonusers may yield most reliable risk estimates. Additionally we found that a healthy user bias may be present in older patients, suggesting that restriction to incident statin users alone will not prevent all biases. These biases may ( partially) explain the wide range of unintended protective effects attributed to statins. Examples are protections against depression (5), chronic obstructive pulmonary disease (6) , and pneumonia (9) that were found in case-control studies where often only prevalent users are considered in the analysis. Examples from cohort studies include Parkinson disease (4), venous thrombosis (7, 8) , and fractures (10) , where statin users (prevalent and incident combined) were compared with nonusers or never users. We therefore recommend stratification for types of statin users and age in cohort studies. This could prevent overoptimistic risk estimates and false positive findings.
This study consisted of a large homogenous and consecutive cohort of atrial fibrillation patients with registration of more than 450 major and 1,650 minor bleeding events. Still, as a limitation of our sample study, numbers became small after stratification by age and incident and prevalent statin users. Additionally, without results from a randomized controlled trial in the population under study, we cannot rule out that our final adjusted findings are attributable to a causal effect, residual confounding, or sampling error. Another potential limitation of this study is that no data were present on the end date of statin use, which may have resulted in a dilution of the risk estimates.
Our findings support the hypothesis that comparing prevalent statin users with nonusers in observational studies leads to biased risk estimates (12) . In addition, we observed that restriction to incident statin users does not necessarily prevent all bias in observational studies on the associations of statins with disease outcomes, because a healthy user bias may be present when comparing older incident statin users with nonusers. Both biases give overoptimistic views on the pleiotropic effects of statins that are similar to what was found in earlier studies on hormone replacement therapy (22, 23) . To conclude, when studying the associations of statins with disease outcomes in cohorts, we recommend stratification by age and by incident and prevalent statin use to avoid overoptimistic risk estimates.
